文献速递心力衰竭与心肌病

硫酸氢伊伐布雷定缓释片治疗收缩性心力衰竭

Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究为随机对照试验,纳入181例安慰剂和179例硫酸氢伊伐布雷定缓释片(SR)的稳定期射血分数降低的心力衰竭(HFrEF)患者,在标准治疗基础上每日一次给药,主要终点为32周左室收缩末期容积指数变化。结果显示SR组改善更显著,并在多个次要终点上优于安慰剂,不良事件总体无差异。

要点

  • 每日一次伊伐布雷定SR在标准治疗基础上改善HFrEF患者心功能。
  • SR组左室收缩末期容积指数改善优于安慰剂。
  • SR组心衰恶化住院和心血管住院少于安慰剂,总体不良事件无差异。

核心结论

  • 在优化标准治疗基础上加用每日一次伊伐布雷定SR可改善HFrEF患者的心功能。

研究设计与样本

  • 随机对照试验,纳入稳定期NYHA II-IV级HFrEF患者,随机分为安慰剂组181例和伊伐布雷定SR组179例。
  • 主要终点为基线至第32周左室收缩末期容积指数的变化。

主要发现

  • 32周时两组左室收缩末期容积指数均较基线改善,伊伐布雷定SR组改善更显著。
  • 伊伐布雷定SR组在左室舒张末期容积指数、左室射血分数、静息心率、堪萨斯城心肌病问卷评分以及心衰恶化和心血管疾病住院方面均优于安慰剂。
  • 总体不良事件两组无差异,伊伐布雷定SR组心衰恶化发生较少。

临床怎么用

  • 对于稳定期HFrEF患者,可考虑在标准治疗基础上加用每日一次伊伐布雷定SR以改善心功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ivabradine has potent actions in reducing heart rate and improving clinical outcomes of chronic heart failure with reduced ejection fraction (HFrEF). At present, only the short-acting formulation of ivabradine is available that needs to be administered twice daily. OBJECTIVES: This study sought to evaluate the role of ivabradine hemisulfate sustained release (SR), a novel long-acting formulation of ivabradine dosed once daily, in stable patients with HFrEF. METHODS: Patients with stabilized HFrEF in New York Heart Association functional class II-IV were enrolled and randomized to receive placebo or ivabradine SR in addition to standard medications. The primary endpoint was the change of left ventricular (LV) end-systolic volume index from baseline to week 32. RESULTS: We randomly assigned 181 patients to placebo and 179 patients to ivabradine SR. After 32 weeks, a significant improvement of LV end-systolic volume index from baseline was observed in both arms with a greater effect in the ivabradine SR arm. Ivabradine SR therapy also exhibited superiority in improving LV end-diastolic volume index, LV ejection fraction, resting heart rate, the Kansas City Cardiomyopathy Questionnaire score, and hospital admission for heart failure worsening and cardiovascular disease in comparison to placebo. Overall adverse events showed no difference between the treatment arms. There were fewer occurrences of worsening heart failure in the ivabradine SR arm. CONCLUSIONS: The present study demonstrates that ivabradine SR once daily in addition to optimum standard therapy improved heart function in patients with HFrEF. (Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets [FIRST]; NCT02188082).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ye, Wang, Wu, et al. Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure. J Am Coll Cardiol. 2022. PMID: 35926931. doi:10.1016/j.jacc.2022.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。